OBJECTIVE: To find out the effect of carmustine (bischloroethyl-nitrosourea) combined with a biodegradable polymer in the treatment of malignant (Grades III and IV) gliomas, applied locally, at the time of the primary operation. METHODS: Prospective, randomized double-blind study of an active treatment group versus a placebo group. Conducted at the Departments of Neurosurgery of the University Hospitals of Helsinki, Tampere, and Turku in Finland and Trondheim in Norway. The study consisted of 32 patients (16 in each treatment group) enrolled between March 23, 1992, and March 19, 1993. The study was planned to include 100 patients but had to be terminated prematurely, because the drug that was being used had become unobtainable. The main outcome measures included the survival times of patients after the operations and the application of an active drug or placebo. RESULTS: The median time from surgery to death was 58.1 weeks for the active treatment group versus 39.9 weeks for the placebo group (P = 0.012). For 27 patients with Grade IV tumors, the corresponding times were 39.9 weeks for the placebo group and 53.3 weeks for the active treatment group (P = 0.008). At the end of the study, six patients were still alive, five of whom belonged to the active treatment group. CONCLUSION:Carmustine applied locally in a biodegradable polymer at the time of primary operation, seems to have a favorable effect on the life span of patients with high-grade gliomas.
RCT Entities:
OBJECTIVE: To find out the effect of carmustine (bischloroethyl-nitrosourea) combined with a biodegradable polymer in the treatment of malignant (Grades III and IV) gliomas, applied locally, at the time of the primary operation. METHODS: Prospective, randomized double-blind study of an active treatment group versus a placebo group. Conducted at the Departments of Neurosurgery of the University Hospitals of Helsinki, Tampere, and Turku in Finland and Trondheim in Norway. The study consisted of 32 patients (16 in each treatment group) enrolled between March 23, 1992, and March 19, 1993. The study was planned to include 100 patients but had to be terminated prematurely, because the drug that was being used had become unobtainable. The main outcome measures included the survival times of patients after the operations and the application of an active drug or placebo. RESULTS: The median time from surgery to death was 58.1 weeks for the active treatment group versus 39.9 weeks for the placebo group (P = 0.012). For 27 patients with Grade IV tumors, the corresponding times were 39.9 weeks for the placebo group and 53.3 weeks for the active treatment group (P = 0.008). At the end of the study, six patients were still alive, five of whom belonged to the active treatment group. CONCLUSION:Carmustine applied locally in a biodegradable polymer at the time of primary operation, seems to have a favorable effect on the life span of patients with high-grade gliomas.
Authors: Prakash Sampath; Laurence D Rhines; Francesco DiMeco; Betty M Tyler; Michael C Park; Henry Brem Journal: J Neurooncol Date: 2006-04-25 Impact factor: 4.130
Authors: Sadhana Jackson; Nicole M Anders; Antonella Mangraviti; Teresia M Wanjiku; Eric W Sankey; Ann Liu; Henry Brem; Betty Tyler; Michelle A Rudek; Stuart A Grossman Journal: J Neurooncol Date: 2015-12-01 Impact factor: 4.130
Authors: Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho Journal: J Natl Compr Canc Netw Date: 2013-09-01 Impact factor: 11.908
Authors: Byron C Masi; Betty M Tyler; Hansen Bow; Robert T Wicks; Yuan Xue; Henry Brem; Robert Langer; Michael J Cima Journal: Biomaterials Date: 2012-05-14 Impact factor: 12.479
Authors: A Boiardi; M Eoli; A Salmaggi; E Lamperti; A Botturi; G Broggi; L Bissola; G Finocchiaro; A Silvani Journal: J Neurooncol Date: 2005-11 Impact factor: 4.130
Authors: Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem Journal: J Neurooncol Date: 2002-06 Impact factor: 4.130
Authors: Xing Fan; Leila Khaki; Thant S Zhu; Mary E Soules; Caroline E Talsma; Naheed Gul; Cheryl Koh; Jiangyang Zhang; Yue-Ming Li; Jarek Maciaczyk; Guido Nikkhah; Francesco Dimeco; Sara Piccirillo; Angelo L Vescovi; Charles G Eberhart Journal: Stem Cells Date: 2010-01 Impact factor: 6.277